bye bye
bye bye
bye bye
CARB-X will invest up to $3m into India-based diagnostics company Module Innovations whichis developing a rapid easy-to-use diagnostic for drug-resistant urinary tract infections (UTI).…
The June issue of ACS Infectious Diseases is a special issue on antibiotics featuring all major stakeholders and perspectives in the AMR community. The…
GARD is looking for a new Board member with high-level executive experience and strategy setting in pharmaceutical/biotech industry. Applications and nominations will be accepted…
Until 31 July 2020 companies developing new treatments to combat AMR are invited to submit proposals. Today, the Novo Holdings REPAIR Impact Fund announced…
CARB-X is investing up to $11m into US-based Microbion to develop its inhaled drug pravibismane to treat cystic fibrosis. CARB-X is awarding Microbion Corporation…